Products Erenumab was approved in many countries, in the EU, and in the United States in 2018 as a solution for injection in a prefilled pen and a prefilled syringe (Aimovig, Novartis / Amgen). Structure and properties Erenumab is a human IgG2 monoclonal antibody directed against the CGRP receptor. It has a molecular weight of … Erenumab
Products Transdermal patches are approved as medicinal products. They offer themselves as an alternative to other modes of application such as peroral and parenteral administration. The first products were launched in the 1970s. Structure and properties Transdermal patches are flexible pharmaceutical preparations of varying sizes and thinness that contain one or more active ingredients. They … Transdermal Patches
Products Erenumab (Aimovig) was the first agent from the group of CGRP inhibitors to be approved in 2018. Fremanezumab (Ajovy) and galcanezumab (Emgality) followed. Structure and properties CGRP inhibitors are humanized or human monoclonal IgG antibodies directed against calcitonin gene-related peptide (CGRP). Low-molecular-weight CGRP receptor antagonists (so-called Gepante) are in clinical development. Some agents have … CGRP Inhibitors
Controlled release from the drug The special design of a drug can be used to achieve delayed, prolonged, continuous, and controlled release of the active ingredient over an extended period of time. This allows the timing, location, and rate of release to be influenced. Galenics Sustained-release drugs include sustained-release tablets, sustained-release capsules, sustained-release granules, and … Retardation
Products LABA is an acronym for , which means long-acting beta agonists (sympathomimetics). LABAs are mainly marketed as inhaled preparations (powders, solutions) administered with an inhaler such as a metered-dose inhaler, diskus, respimat, breezhaler, or ellipta. Some may also be given perorally. Salmeterol and formoterol were the first agents from this group to be approved … LABA
Products Baloxavirmarboxil was approved in film-coated tablet form in Japan and the United States in 2018 and in many countries in 2020 (Xofluza). Structure and properties Baloxavirmarboxil (C27H23F2N3O7S, Mr = 571.5 g/mol) is a prodrug of baloxavir (synonym: baloxaviric acid). It is converted to the active drug by hydrolysis. It is practically insoluble in water. … Baloxavirmarboxil
Definition In a medication analysis, the medications that a patient is using are reviewed by a healthcare professional for various aspects. The objectives of the analysis include the following: Optimization of therapy and use, improvement of health status. Avoidance of adverse effects and drug-drug interactions. Increasing adherence to therapy Discontinuation of unnecessary medication Recognizing risks … Medication Analysis
Definition and discussion Dosing interval (symbol: τ, tau) is the time interval between the administration of individual doses of a drug. For example, if 1 tablet is administered at 8 AM and 1 tablet is administered at 8 PM, the dosing interval is 12 hours. The typical dosing interval is several hours or one day. … Dosage Interval
Products Vilanterol is commercially available as a fixed combination with fluticasone furoate in powder inhaler form (Relvar Ellipta / Breo Ellipta). It was approved in the US and EU in 2013 and in many countries in 2014. The fixed combination with umeclidinium bromide (Anoro Ellipta) was also registered in many countries in 2014. In 2017, … Vilanterol
Products Immunosuppressants are commercially available in numerous dosage forms, for example, as creams, ointments, tablets, capsules, solutions, eye drops, and injectables. Structure and properties Within immunosuppressants, several groups can be identified. These include steroids such as the glucocorticoids, substances of microbiological origin such as ciclosporin and mycophenolate mofetil, derivatives of nucleic acids and their components … Immunosuppressants
